Cathie Wood Sells $5.2 Million in AI Stock; Discover What Ark Invest Acquired in Its Place
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Should l Buy TEM?
Source: Benzinga
Ark Invest's Sale of Tempus AI Shares: Ark Invest, led by Cathie Wood, sold 62,352 shares of Tempus AI Inc for approximately $5.2 million, despite the company recently receiving FDA clearance for its RNA-based diagnostic device.
Recent Trading Activity: The firm has been reducing its position in Tempus AI over the past few weeks, having sold shares worth $3.76 million and $2.1 million in earlier transactions, while also making other trades in companies like Arcturus Therapeutics and Roku.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 49.140
Low
76.00
Averages
84.38
High
105.00
Current: 49.140
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AI Drug Discovery Efficiency Boost
- Drug Discovery Efficiency: Recursion Pharmaceuticals synthesizes an average of 330 compounds in 17 months, significantly outperforming the industry average of 2,500 compounds over 42 months, thereby accelerating new drug development and enhancing market competitiveness.
- Substantial Partnership Revenue: Recursion has secured $213 million in fees from collaborations with Roche and Genentech, highlighting the commercial value of its proprietary whole-genome CRISPR knockout maps, which further solidifies its leadership in the biopharmaceutical sector.
- Tempus AI's Market Potential: Tempus AI's trailing revenue reached $1.27 billion, growing approximately 30% annually, with its unique clinical data library and AI analytics positioning it as a key player in precision medicine, attracting numerous pharmaceutical partnerships.
- Future Growth Expectations: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets implying over 60% upside for the stock in the next year, reflecting strong market confidence in its long-term growth potential.
See More
The Future of Drug Discovery Driven by AI
- Efficiency in Drug Discovery: Recursion Pharmaceuticals has revolutionized drug development by synthesizing an average of 330 compounds in just 17 months, compared to the industry average of 2,500 compounds over 42 months, indicating a significant potential to disrupt traditional pharmaceutical processes.
- Substantial Partnership Revenue: With over $500 million in cumulative milestone payments and its first clinical proof-of-concept demonstrating the efficacy of AI-discovered molecules in real patients, Recursion showcases a promising commercial outlook that could lead to profitability in the future.
- Market Growth of Tempus AI: Tempus AI has achieved trailing revenue of $1.27 billion, growing approximately 30% annually, and its unique clinical data relationships make it nearly impossible for competitors to replicate, solidifying its leadership in precision medicine.
- Future Growth Potential: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets suggesting over 60% upside for the stock in the next year, highlighting its critical role in the transformation of the healthcare industry.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: ARKK ETF's 52-week low is $38.5686 per share and high is $92.65, with the latest trade at $69.69, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify notable inflows (new units created) or outflows (old units destroyed), which can affect the individual components held within ETFs and subsequently influence overall market performance.
See More
Tempus Partners with Blood Cancer United to Develop Pediatric Leukemia Registry
- Strategic Collaboration: Tempus AI and Blood Cancer United have announced a partnership to develop a patient-centered real-world registry for pediatric acute myeloid leukemia, aimed at empowering patients with health data and driving scientific breakthroughs.
- Technology Platform Utilization: The initiative will leverage Tempus' olivia app to centralize patient health data and provide personalized educational materials, ensuring patients receive timely and relevant information throughout their treatment journey, thereby enhancing patient experience and engagement.
- Data Collection and Analysis: olivia will collect longitudinal electronic patient-reported outcomes and questionnaire data, combined with Tempus' Lens analytics platform, to create one of the largest pediatric acute myeloid leukemia registries to date, facilitating the development of new therapies.
- Future Outlook: This collaboration not only provides better support and resources for pediatric leukemia patients but also accelerates clinical trial processes by integrating patient-reported outcomes with de-identified medical and genomic data, ensuring more children can access innovative therapies.
See More
Tempus AI Shares Rise as Analyst Reiterates Buy Rating
- Analyst Rating Reiteration: Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI with a $75 price target, reflecting confidence in the company's growth potential and likely attracting more investor interest.
- Research Findings Published: Tempus announced a new study in JCO Precision Oncology that highlights the value of advanced genomic profiling tools in identifying clinically actionable findings in community oncology, potentially solidifying the company's leadership in precision medicine.
- Actionable Findings Ratio: The study revealed that approximately 12% of patients in the pilot and expanded cohorts had potentially actionable findings linked to approved therapies identified solely through advanced testing features, indicating the effectiveness of the company's technology and market demand.
- Stock Price Volatility Trend: Despite Tempus AI's stock experiencing fluctuations from $37.23 to $103.25 over the past year, it currently trades at $52.85, remaining below its 20-day, 50-day, and 200-day moving averages, signaling ongoing downside pressure.
See More
Tempus AI Study Advances Precision Medicine with Genomic Profiling
- Significant Findings: A study by Tempus AI in collaboration with The Oncology Institute reveals that 12% (approximately 1 in 8) of patients identified actionable findings through advanced genomic profiling techniques, such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing, underscoring the importance of comprehensive genomic profiling in community oncology.
- Need for Precision Medicine: The research highlights that current treatment guidelines lack specificity regarding the composition of genomic profiling panels, emphasizing the clinical necessity of utilizing the most comprehensive tools available to ensure patients receive optimal treatment options, thereby enhancing Tempus's strategic position in precision medicine.
- Expanded Clinical Applications: By providing a more comprehensive view of clinically relevant findings, Tempus's advanced testing capabilities not only broaden access to targeted treatments and clinical trial opportunities but also equip clinicians with richer information support, facilitating the implementation of precision medicine.
- Innovation-Driven Technology: Tempus leverages one of the world's largest multimodal data libraries and applies artificial intelligence to advance precision medicine, aiming to deliver personalized treatment solutions for each patient through continuous learning and data accumulation, further solidifying its leadership in the healthcare technology sector.
See More
AI Drug Discovery Efficiency Boost
- Drug Discovery Efficiency: Recursion Pharmaceuticals synthesizes an average of 330 compounds in 17 months, significantly outperforming the industry average of 2,500 compounds over 42 months, thereby accelerating new drug development and enhancing market competitiveness.
- Substantial Partnership Revenue: Recursion has secured $213 million in fees from collaborations with Roche and Genentech, highlighting the commercial value of its proprietary whole-genome CRISPR knockout maps, which further solidifies its leadership in the biopharmaceutical sector.
- Tempus AI's Market Potential: Tempus AI's trailing revenue reached $1.27 billion, growing approximately 30% annually, with its unique clinical data library and AI analytics positioning it as a key player in precision medicine, attracting numerous pharmaceutical partnerships.
- Future Growth Expectations: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets implying over 60% upside for the stock in the next year, reflecting strong market confidence in its long-term growth potential.
See More
The Future of Drug Discovery Driven by AI
- Efficiency in Drug Discovery: Recursion Pharmaceuticals has revolutionized drug development by synthesizing an average of 330 compounds in just 17 months, compared to the industry average of 2,500 compounds over 42 months, indicating a significant potential to disrupt traditional pharmaceutical processes.
- Substantial Partnership Revenue: With over $500 million in cumulative milestone payments and its first clinical proof-of-concept demonstrating the efficacy of AI-discovered molecules in real patients, Recursion showcases a promising commercial outlook that could lead to profitability in the future.
- Market Growth of Tempus AI: Tempus AI has achieved trailing revenue of $1.27 billion, growing approximately 30% annually, and its unique clinical data relationships make it nearly impossible for competitors to replicate, solidifying its leadership in precision medicine.
- Future Growth Potential: Analysts project nearly 30% annual revenue growth for Tempus AI over the next three years, with consensus price targets suggesting over 60% upside for the stock in the next year, highlighting its critical role in the transformation of the healthcare industry.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: ARKK ETF's 52-week low is $38.5686 per share and high is $92.65, with the latest trade at $69.69, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify notable inflows (new units created) or outflows (old units destroyed), which can affect the individual components held within ETFs and subsequently influence overall market performance.
See More
Tempus Partners with Blood Cancer United to Develop Pediatric Leukemia Registry
- Strategic Collaboration: Tempus AI and Blood Cancer United have announced a partnership to develop a patient-centered real-world registry for pediatric acute myeloid leukemia, aimed at empowering patients with health data and driving scientific breakthroughs.
- Technology Platform Utilization: The initiative will leverage Tempus' olivia app to centralize patient health data and provide personalized educational materials, ensuring patients receive timely and relevant information throughout their treatment journey, thereby enhancing patient experience and engagement.
- Data Collection and Analysis: olivia will collect longitudinal electronic patient-reported outcomes and questionnaire data, combined with Tempus' Lens analytics platform, to create one of the largest pediatric acute myeloid leukemia registries to date, facilitating the development of new therapies.
- Future Outlook: This collaboration not only provides better support and resources for pediatric leukemia patients but also accelerates clinical trial processes by integrating patient-reported outcomes with de-identified medical and genomic data, ensuring more children can access innovative therapies.
See More
Tempus AI Shares Rise as Analyst Reiterates Buy Rating
- Analyst Rating Reiteration: Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI with a $75 price target, reflecting confidence in the company's growth potential and likely attracting more investor interest.
- Research Findings Published: Tempus announced a new study in JCO Precision Oncology that highlights the value of advanced genomic profiling tools in identifying clinically actionable findings in community oncology, potentially solidifying the company's leadership in precision medicine.
- Actionable Findings Ratio: The study revealed that approximately 12% of patients in the pilot and expanded cohorts had potentially actionable findings linked to approved therapies identified solely through advanced testing features, indicating the effectiveness of the company's technology and market demand.
- Stock Price Volatility Trend: Despite Tempus AI's stock experiencing fluctuations from $37.23 to $103.25 over the past year, it currently trades at $52.85, remaining below its 20-day, 50-day, and 200-day moving averages, signaling ongoing downside pressure.
See More
Tempus AI Study Advances Precision Medicine with Genomic Profiling
- Significant Findings: A study by Tempus AI in collaboration with The Oncology Institute reveals that 12% (approximately 1 in 8) of patients identified actionable findings through advanced genomic profiling techniques, such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing, underscoring the importance of comprehensive genomic profiling in community oncology.
- Need for Precision Medicine: The research highlights that current treatment guidelines lack specificity regarding the composition of genomic profiling panels, emphasizing the clinical necessity of utilizing the most comprehensive tools available to ensure patients receive optimal treatment options, thereby enhancing Tempus's strategic position in precision medicine.
- Expanded Clinical Applications: By providing a more comprehensive view of clinically relevant findings, Tempus's advanced testing capabilities not only broaden access to targeted treatments and clinical trial opportunities but also equip clinicians with richer information support, facilitating the implementation of precision medicine.
- Innovation-Driven Technology: Tempus leverages one of the world's largest multimodal data libraries and applies artificial intelligence to advance precision medicine, aiming to deliver personalized treatment solutions for each patient through continuous learning and data accumulation, further solidifying its leadership in the healthcare technology sector.
See More
